DoD Spends $51M on Abbott BinaxNow Test Kits via Full and Open Competition

Contract Overview

Contract Amount: $51,000,000 ($51.0M)

Contractor: Abbott Rapid DX North America LLC

Awarding Agency: Department of Defense

Start Date: 2021-07-13

End Date: 2022-09-12

Contract Duration: 426 days

Daily Burn Rate: $119.7K/day

Competition Type: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: 8508356527!BINAXNOW TEST KIT (EA)

Place of Performance

Location: ORLANDO, ORANGE County, FLORIDA, 32810

State: Florida Government Spending

Plain-Language Summary

Department of Defense obligated $51.0 million to ABBOTT RAPID DX NORTH AMERICA LLC for work described as: 8508356527!BINAXNOW TEST KIT (EA) Key points: 1. Significant investment in critical diagnostic supplies for the Department of Defense. 2. Abbott Rapid Dx North America LLC secured the contract, indicating a key supplier in the market. 3. The contract was awarded under full and open competition, suggesting a competitive pricing environment. 4. The 'In-Vitro Diagnostic Substance Manufacturing' sector highlights the specialized nature of this procurement.

Value Assessment

Rating: good

The contract value of $51 million for BinaxNow test kits appears reasonable given the scale and urgency of pandemic-related needs. Benchmarking against similar large-volume diagnostic procurements during the pandemic would provide further context.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under 'FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES,' indicating that multiple bidders were considered after an initial exclusion period. This method generally promotes competitive pricing and ensures the government receives best value.

Taxpayer Impact: The competitive award process likely resulted in a fair price for taxpayers, ensuring value for money on essential medical supplies.

Public Impact

Ensures availability of critical COVID-19 testing supplies for military personnel and potentially their families. Supports the Department of Defense's public health and readiness mission. Highlights the government's reliance on established manufacturers for rapid diagnostic solutions.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Positive Signals

Sector Analysis

The procurement falls within the 'In-Vitro Diagnostic Substance Manufacturing' sector, a critical area for public health and national security. Spending benchmarks in this sector are highly variable, influenced by global demand, supply chain constraints, and the specific nature of the diagnostic technology.

Small Business Impact

The data indicates the prime contractor is ABBOTT RAPID DX NORTH AMERICA LLC, a large business. There is no specific information provided regarding small business participation in this contract, suggesting it may not have been a primary focus or was subcontracted out.

Oversight & Accountability

The contract was awarded by the Defense Logistics Agency, a key procurement arm for the DoD. Oversight would involve monitoring delivery schedules, quality control, and adherence to the firm fixed price terms to ensure accountability and taxpayer value.

Related Government Programs

Risk Flags

Tags

in-vitro-diagnostic-substance-manufactur, department-of-defense, fl, delivery-order, 10m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $51.0 million to ABBOTT RAPID DX NORTH AMERICA LLC. 8508356527!BINAXNOW TEST KIT (EA)

Who is the contractor on this award?

The obligated recipient is ABBOTT RAPID DX NORTH AMERICA LLC.

Which agency awarded this contract?

Awarding agency: Department of Defense (Defense Logistics Agency).

What is the total obligated amount?

The obligated amount is $51.0 million.

What is the period of performance?

Start: 2021-07-13. End: 2022-09-12.

What was the unit price of the BinaxNow test kits, and how does it compare to market rates at the time of award?

The provided data does not include the unit price, only the total contract value of $51 million. To assess value, the total quantity of test kits procured would be needed to calculate a per-unit cost. This would then need to be benchmarked against prevailing market prices for similar rapid diagnostic tests during the 2021-2022 period, considering bulk purchasing discounts and specific contract terms.

What were the specific reasons for excluding other sources initially, and did this exclusion impact the final price?

The data states 'FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES' without detailing the initial exclusion reasons. Typically, such exclusions might be due to specific technical requirements, existing contracts, or urgent needs. While full and open competition generally drives down prices, the initial exclusion could have limited the pool of bidders, potentially impacting the final price discovery compared to a truly unrestricted competition from the outset.

How effectively did these test kits contribute to the Department of Defense's COVID-19 response and operational readiness?

The effectiveness of the BinaxNow test kits in supporting the DoD's COVID-19 response and operational readiness is not directly quantifiable from this contract data alone. However, the significant investment suggests a perceived need for widespread testing capabilities. The actual impact would depend on deployment strategies, testing frequency, accuracy of results in real-world conditions, and how quickly positive cases could be managed to maintain force health protection and mission capability.

Industry Classification

NAICS: ManufacturingPharmaceutical and Medicine ManufacturingIn-Vitro Diagnostic Substance Manufacturing

Product/Service Code: INSTRUMENTS AND LABORATORY EQPT

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Abbott Laboratories

Address: 30 S KELLER RD STE 100, ORLANDO, FL, 32810

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $51,000,000

Exercised Options: $51,000,000

Current Obligation: $51,000,000

Actual Outlays: $50,989,800

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: SPE2DE21D0023

IDV Type: IDC

Timeline

Start Date: 2021-07-13

Current End Date: 2022-09-12

Potential End Date: 2022-09-12 00:00:00

Last Modified: 2025-04-24

More Contracts from Abbott Rapid DX North America LLC

View all Abbott Rapid DX North America LLC federal contracts →

Other Department of Defense Contracts

View all Department of Defense contracts →

Explore Related Government Spending